Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vectus Biosystems Limited ( (AU:VBS) ) just unveiled an update.
Vectus Biosystems Limited held its Annual General Meeting on November 26, 2025, where all proposed resolutions were passed. These included the re-election of Ronald Shnier as a director, the election of Linda Walters as a director, and the adoption of the remuneration report. The successful passing of these resolutions indicates strong shareholder support and may positively impact the company’s governance and strategic direction.
The most recent analyst rating on (AU:VBS) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Vectus Biosystems Limited stock, see the AU:VBS Stock Forecast page.
More about Vectus Biosystems Limited
Vectus Biosystems Limited operates in the biotechnology industry, focusing on developing therapeutic treatments for fibrosis and high blood pressure-related disorders. The company is dedicated to advancing its proprietary technology to address unmet medical needs in these areas.
Average Trading Volume: 88,110
Technical Sentiment Signal: Hold
Current Market Cap: A$10.4M
Learn more about VBS stock on TipRanks’ Stock Analysis page.